About: Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 10 September 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) artículu científicu espublizáu en setiembre de 2019 (ast) scientific article published on 10 September 2019 (en) 2019 թվականի սեպտեմբերի 10-ին հրատարակված գիտական հոդված (hy) наукова стаття, опублікована 10 вересня 2019 (uk) 2019 സപ്തംബര്‍ 10 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം (ml)
publication date	wds:Q90096830-CDA76B27-E7D0-4BCA-B6FC-AFA45F499030
publication date	2019-09-10 00:00:00Z (xsd:dateTime)
cites work	wds:Q90096830-215DFF61-6873-4647-B92F-D7A3A18BC5E1 wds:Q90096830-220692E5-2978-4C00-8F5B-D81F088E07CA wds:Q90096830-261C02B1-E8FD-4BEB-ABED-F064F3E649E7 wds:Q90096830-286E77F0-E268-409A-8F78-6BDF6C99B6BA wds:Q90096830-30285A0B-1FD9-43AD-A0B4-20AF7C7A7367 wds:Q90096830-31731417-80BF-44AA-B3BC-3024411173F5 wds:Q90096830-3472E68C-CD22-4150-ADF4-72552F93FC59 wds:Q90096830-4AB35B74-AD15-4A76-A517-E07026A58778 wds:Q90096830-5FEB5991-BA87-408B-AE9B-35C52DEC7D7E wds:Q90096830-65D95AFD-8DB0-46AB-871A-038343AAD938 wds:Q90096830-69595752-7E6F-4449-94B6-C1325BF3B4F7 wds:Q90096830-6B1E054A-F461-4ADA-BB1E-D2C4ABE62D2A wds:Q90096830-744A004E-301A-4003-8C3A-13FA45148D51 wds:Q90096830-7670FCCA-59FA-468F-8906-98030215DB3D wds:Q90096830-7B415B17-4779-471B-ADED-5A5751C132D4 wds:Q90096830-7E46B64B-588E-424C-B402-6CAAF85F87B5 wds:Q90096830-84FB9F3F-1782-4A3A-9FFC-F49D4A163AB7 wds:Q90096830-8A83D348-C8CD-4EED-9155-7A2A21081B47 wds:Q90096830-8DEAEC34-8862-406B-9926-D24DEFF2F82F wds:Q90096830-90673DF9-FAA0-47AE-912A-9DC589EDD120 wds:Q90096830-931EE8BD-4421-4285-A35A-52727CA0B1A0 wds:Q90096830-96AEDBEA-770A-42C7-84CF-FD38B2268DB3 wds:Q90096830-97857037-34EC-4762-A8D1-63823A0D0AE0 wds:Q90096830-97F293E5-34E0-44C0-8161-C90CD8E3DD34 wds:Q90096830-9ACC3F4E-6C56-4D84-B536-15D9571F29F5 wds:Q90096830-B6D2B20E-9D9A-44FB-A238-9B8DB2B86B9F wds:Q90096830-BBC08511-D7D3-43EA-A415-00CE26F3BCB0 wds:Q90096830-C57172F9-3825-4954-9826-AD9943F551FD wds:Q90096830-D81C4CD0-056A-4409-8C6D-B4E25AC045AC wds:Q90096830-E2DCD0CA-829D-435A-A1B7-594368870C40 wds:Q90096830-E4561D19-A6DD-474E-A35B-8E3C4061A0F0 wds:Q90096830-E75DC175-42B4-42A7-A311-A84986CF27A0 wds:Q90096830-ECC853E6-DA9D-4A8B-A5D1-79F198B33C0D wds:Q90096830-F49D383E-2AE5-47BD-A6F6-207C7152C2E1 wds:Q90096830-FE324782-EC25-402F-B437-7ED00B1D7CD2
cites work	Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics Reporting birth defects surveillance data 1968-2003. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts Thalidomide-induced limb defects: resolving a 50-year-old puzzle A compartmental absorption and transit model for estimating oral drug absorption. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy Ontogeny of human hepatic cytochromes P450. Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. Enrolling pregnant women: issues in clinical research Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding Quantitative standards for fetal and neonatal autopsy A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4 Thalidomide metabolism and hydrolysis: mechanisms and implications Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. Placental thickness & its correlation to gestational age & foetal growth parameters- a cross sectional ultrasonographic study Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients Assessment of changes in blood flow through the lungs and foramen ovale in the normal human fetus with gestational age: a prospective Doppler echocardiographic study Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study Human hepatic CYP2B6 developmental expression: the impact of age and genotype Thalidomide-induced teratogenesis: history and mechanisms Normal Organ Weights in Women: Part II-The Brain, Lungs, Liver, Spleen, and Kidneys Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice.
author name string	wds:Q90096830-3C523729-A59D-4350-B197-DA8C2035058B wds:Q90096830-4B8F31B0-6FB1-4A0D-907B-BE4226590C01 wds:Q90096830-5B2E8423-8985-4359-890C-DD6D19807E53 wds:Q90096830-5BC6AED9-D894-4F71-BA51-749B47B3C74A wds:Q90096830-84A5457A-46E5-418E-9DC7-08CE49D200BF wds:Q90096830-E6B2AB49-C338-4074-9F74-263F4C5CDEC1 wds:Q90096830-EFB14841-7E0A-41D7-8083-FAB62B7C50A5
author name string	Andrew Owen Marco Siccardi Ebunoluwa Adejuyigbe Adeniyi Olagunju Rajith K R Rajoli Oluseye Bolaji Shakir Adeyinka Atoyebi
rdfs:label	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies (en) Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies (nl)
skos:prefLabel	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies (en) Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies (nl)
name	Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies (en) Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies (nl)
title	wds:Q90096830-2411AD27-0F7C-4098-A96F-8ABEBF332A1B

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software